Skip to main content

Table 1 Study participant demographics and clinical characteristics

From: Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

Variable

All participants (n = 13)

Non-controllers (n = 10)

Controllers (n = 3)

Demographics

 Sex (M/F), n

12/1

9/1

3/0

 Risk group (MSM/HTS), n

12/1

9/1

3/0

 Ethnic group (Caucasian/Latin), n

12/1

9/1

3/0

 Age (years)

42 (39–47)

43 (39–47)

34 (33–38)

 BMI (kg/m2)

22.9 (20.9–24)

22.3 (21.1–23.4)

24.3 (22.2–25)

Treatment and clinical characteristics

 ART regimen, n (TDF_FTC_RAL/ABC_3TC_RAL/ABC_3TC_DTG)

2/9/2

2/6/2

0/3/0

 Viral reservoir (HIV-1 DNA cp/106 CD4+ T-cells)

140 (65–361)

165 (76.2–415.7)

65 (62.5–116.5)

 CD4+ T cell (cells/mm3)

728 (648–1182)

839 (581.8–1293.8)

657 (652.5–814)

 CD4+ T cell (%)

42.9 (42.2–49.3)

43.4 (42.3–48.1)

42.2 (38.4–48.1)

 CD4/CD8 T cell counts ratio

1.4 (1.2–1.6)

1.4 (1.2–1.5)

1.3 (1.1–1.6)

  1. Continuous data are presented using median, 25% and 75% interquartile range, unless otherwise described
  2. No statistically significant differences were observed (p ≤ 0.05; Wilcoxon rank-sum test)
  3. M Male, F Female, MSM Men who have sex with men, HTS Heterosexual, BMI Body mass index, ART Antiretroviral therapy, cp Copies, TDF Tenofovir disoproxil fumarate, FTC Emtricitabine, RAL Raltegravir, ABC Abacavir, 3TC Lamivudine, DTG Dolutegravir